POTENTIAL OF IMIDAZOLINE RECEPTOR AGONISTS IN THE TREATMENT OF ARTERIAL HYPERTENSION

Esler M. Sympathetic nervous system: contribution to human hypertension and related cardiovascular disease. J Cardiovasc Pharmacol. 1995;26(2):S24–28.

Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998;19(F):F14–18.

Bousquet P., Feldman J., Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther. 1984;230(1):232–236.

Parini A. Du recepteur alpha-2 adrenergique au recepteur imidazoline - guanidinique: un concept en evolution. Lettre du Pharmacol. 1989;6:3–5.

Nebieridze D.V., Britov A.N., Aparina T.V. and others. Moxonidine is a modern drug of choice for arterial hypertension and metabolic disorders. Cardiology. 1999;39(1):43–47. [Nebieridze DV, Britov AN, Aparina TV et al. Moxonidine is the modern drug of choice for hypertension and metabolic disorders. Cardiology. 1999;39(1):43–47 (in Russ.)].

Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycemic control in patients with arterial hypertension and overweight compared with metformin: the DIAMOND study. Reviews of Clinical Cardiology. 2007;(9):36–47. [Chazova IE, Almazov VA, Shlyakhto EV Moxonidine improves glycemic control in patients with arterial hypertension and excess body weight in comparison with metformin: the ALMAZ study. Clinical Cardiology Reviews. 2007;(9):36–47 (in Russ.)].

Julius S., Gudbradson T., Jamerson K. et al. The hemodynamic link between insulin resistance and hypertension. J Hypertension. 1991;9;983–986.

Nebieridze D.V., Kamyshova T.V. Imidazoline receptor agonists: do we all know about their capabilities? Rational pharmacotherapy in cardiology. 2012;8(2):233–236. [Nebieridze DV, Kamyshova TV Imidazoline receptor agonists: do we all know about their capabilities? Rational pharmacotherapy in cardiology. 2012;8(2):233–236 (in Russ.)].

Rosen P., Ohly P., Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens Suppl. 1997;15(1):S31–8.

Zhernakova Yu.V., Chazova I.E. Features of the treatment of arterial hypertension in perimenopausal women. Systemic hypertension. 2014;11(1):5–10. [Zhernakova Yu.V., Chazova IE Features of the treatment of arterial hypertension in perimenopausal women. Systemic hypertension. 2014;11(1):5–10 (in Russ.)].

Haenni A., Lithell HO Moxonidin improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999;17(3):S29–S35.

Chazova I., Schlaich MP Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY Study. Intern J Hypertens. 2013;1–9; DOI:10.1155/2013/541689.

Strojek K., Grzeszczak W., Gorska J. et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001;12(3):602–5.

Amman K., Rump LC, Simonavicience A. et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;1:1469–78.

Ametov A.S., Demidova T.Yu., Smagina L.V. Cardio- and nephroprotective effects of the imidazoline receptor agonist moxonidine in the treatment of arterial hypertension in patients with type 2 diabetes mellitus. Diabetes. 2004;7(4):8–13. [Ametov AS, Demidova T.Yu., Smagina LV The cardio- and nephroprotective effects of the imidazoline receptor agonist moxonidine in the treatment of hypertension in patients with type 2 diabetes. Diabetes. 2004;7(4):8–13 (in Russ.)].

Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.

Krespi PG, Makris TK, Hatzizacharias AN et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor — 1 levels in patients with essential hypertension. J Cardiovasc Drugs and Therapy 1998;12:463–467.

National recommendations for the diagnosis and treatment of arterial hypertension. Cardiovascular therapy and prevention. 2008;7(6):1–36. [National guidelines for diagnosis and treatment of hypertension. Cardiovascular Therapy and Prevention. 2008;7(6):1–36 (in Russ.)].

Ibadova, O. A., Shodikulova, G. Z., Najmiddinov, A. Sh. (2021). DIFFICULTIES IN DIFFERENTIAL DIAGNOSIS OF NON-SPECIFIC INTERSTITIAL PNEUMONIA. Achievements of science and education, (8 (80)), 50-55

Shodikulova Gulandom Zikriyayevna, Najmiddinov Alisher Shavkatovich, Mansurov Dilmurod Norimovich.

HEMODYNAMIC CHANGES IN PATIENTS WITH FIBROUS ALVEOLITIS. Spectrum Journal of Innovation, Reforms and Development 2022/6/22.

Gulandom Zikriyaevna Shodikulova, Alisher Shavkatovich Najmiddinov. A MODERN VIEW ON T

HE PROBLEM OF HEART RHYTHM IN PATIENTS WITH INTERSTITIAL PNEUMONIA (LITERATURE REVIEW) the theory of recent scientific research in the field of pedagogy. 2023/3/3.